DE10238257B4 - Sorbicillacton A und Sorbicillacton-A-Derivate, Verfahren zu ihrer Herstellung und sie enthaltende Arzneimittel - Google Patents
Sorbicillacton A und Sorbicillacton-A-Derivate, Verfahren zu ihrer Herstellung und sie enthaltende Arzneimittel Download PDFInfo
- Publication number
- DE10238257B4 DE10238257B4 DE10238257A DE10238257A DE10238257B4 DE 10238257 B4 DE10238257 B4 DE 10238257B4 DE 10238257 A DE10238257 A DE 10238257A DE 10238257 A DE10238257 A DE 10238257A DE 10238257 B4 DE10238257 B4 DE 10238257B4
- Authority
- DE
- Germany
- Prior art keywords
- alkyl
- sorbicillactone
- compound
- branched
- straight
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- JACNBJFTXZEQNC-CVHNVBPNSA-N (e)-4-[[(3s,3ar,4z,7as)-5-hydroxy-4-[(2e,4e)-1-hydroxyhexa-2,4-dienylidene]-3,6,7a-trimethyl-2,7-dioxo-3ah-1-benzofuran-3-yl]amino]-4-oxobut-2-enoic acid Chemical compound O=C1C(C)=C(O)C(=C(\O)/C=C/C=C/C)/[C@@H]2[C@](C)(NC(=O)\C=C\C(O)=O)C(=O)O[C@@]21C JACNBJFTXZEQNC-CVHNVBPNSA-N 0.000 title claims abstract description 67
- WVVJWXDENDJFEC-UHFFFAOYSA-N sorbicillactone A Natural products CC=CC=CC(=C1/C2C(C)(NC(=O)C=CC(=O)O)C(=O)OC2(C)C(=C(C)C1=O)O)O WVVJWXDENDJFEC-UHFFFAOYSA-N 0.000 title claims abstract description 52
- 238000000034 method Methods 0.000 title claims description 23
- 230000008569 process Effects 0.000 title claims description 12
- 238000002360 preparation method Methods 0.000 title claims description 8
- 239000003814 drug Substances 0.000 title description 7
- 229940079593 drug Drugs 0.000 title description 5
- 125000002252 acyl group Chemical group 0.000 claims abstract description 14
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 claims abstract description 12
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 12
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract description 10
- 239000001257 hydrogen Substances 0.000 claims abstract description 10
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims abstract description 9
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims abstract description 9
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 claims abstract description 9
- 125000000349 (Z)-3-carboxyprop-2-enoyl group Chemical group O=C([*])/C([H])=C([H])\C(O[H])=O 0.000 claims abstract description 7
- UTQNKKSJPHTPBS-UHFFFAOYSA-N 2,2,2-trichloroethanone Chemical group ClC(Cl)(Cl)[C]=O UTQNKKSJPHTPBS-UHFFFAOYSA-N 0.000 claims abstract description 7
- 125000004080 3-carboxypropanoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C(O[H])=O 0.000 claims abstract description 7
- QIQCZROILFZKAT-UHFFFAOYSA-N tetracarbon dioxide Chemical group O=C=C=C=C=O QIQCZROILFZKAT-UHFFFAOYSA-N 0.000 claims abstract description 7
- 125000003342 alkenyl group Chemical group 0.000 claims abstract description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims abstract description 3
- 150000002148 esters Chemical class 0.000 claims abstract description 3
- 150000004702 methyl esters Chemical class 0.000 claims abstract description 3
- 150000001875 compounds Chemical class 0.000 claims description 48
- 239000000126 substance Substances 0.000 claims description 29
- 241000233866 Fungi Species 0.000 claims description 16
- 239000000243 solution Substances 0.000 claims description 14
- 241000243142 Porifera Species 0.000 claims description 10
- 239000008194 pharmaceutical composition Substances 0.000 claims description 10
- 230000015572 biosynthetic process Effects 0.000 claims description 9
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims description 8
- 239000002243 precursor Substances 0.000 claims description 8
- 238000003786 synthesis reaction Methods 0.000 claims description 8
- RKKPUBAAIGFXOG-YTXTXJHMSA-N Sorbicillin Chemical compound C\C=C\C=C\C(=O)C1=CC(C)=C(O)C(C)=C1O RKKPUBAAIGFXOG-YTXTXJHMSA-N 0.000 claims description 7
- 239000001963 growth medium Substances 0.000 claims description 7
- 238000001727 in vivo Methods 0.000 claims description 7
- 229940041514 candida albicans extract Drugs 0.000 claims description 6
- 239000012138 yeast extract Substances 0.000 claims description 6
- 238000010790 dilution Methods 0.000 claims description 5
- 239000012895 dilution Substances 0.000 claims description 5
- 239000013535 sea water Substances 0.000 claims description 5
- SJEYUYPBCPRFNM-UHFFFAOYSA-N sorbicillinol Natural products CC=CC=CC(=O)C1=CC(C)(O)C(=O)C(=C1O)C SJEYUYPBCPRFNM-UHFFFAOYSA-N 0.000 claims description 5
- 241000377427 Sarcotragus fasciculatus Species 0.000 claims description 4
- 150000003839 salts Chemical class 0.000 claims description 4
- 239000012453 solvate Substances 0.000 claims description 4
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 4
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims description 3
- 239000002028 Biomass Substances 0.000 claims description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 3
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims description 3
- 241000228150 Penicillium chrysogenum Species 0.000 claims description 3
- 239000001888 Peptone Substances 0.000 claims description 3
- 108010080698 Peptones Proteins 0.000 claims description 3
- 235000004279 alanine Nutrition 0.000 claims description 3
- 235000001014 amino acid Nutrition 0.000 claims description 3
- 150000001413 amino acids Chemical class 0.000 claims description 3
- 230000003592 biomimetic effect Effects 0.000 claims description 3
- 239000002775 capsule Substances 0.000 claims description 3
- 239000008298 dragée Substances 0.000 claims description 3
- 239000001530 fumaric acid Substances 0.000 claims description 3
- 239000008103 glucose Substances 0.000 claims description 3
- 238000001802 infusion Methods 0.000 claims description 3
- 238000002347 injection Methods 0.000 claims description 3
- 239000007924 injection Substances 0.000 claims description 3
- -1 malt extract Substances 0.000 claims description 3
- 230000001590 oxidative effect Effects 0.000 claims description 3
- 235000019319 peptone Nutrition 0.000 claims description 3
- 239000000829 suppository Substances 0.000 claims description 3
- 239000003826 tablet Substances 0.000 claims description 3
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 2
- 239000000654 additive Substances 0.000 claims description 2
- 238000001212 derivatisation Methods 0.000 claims description 2
- 239000006196 drop Substances 0.000 claims description 2
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 claims description 2
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 2
- 125000003226 pyrazolyl group Chemical group 0.000 claims description 2
- 238000009395 breeding Methods 0.000 claims 1
- 230000001488 breeding effect Effects 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 230000002538 fungal effect Effects 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 210000004027 cell Anatomy 0.000 description 32
- 238000011282 treatment Methods 0.000 description 25
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 17
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 15
- 206010028980 Neoplasm Diseases 0.000 description 15
- 201000010099 disease Diseases 0.000 description 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 14
- 241000700605 Viruses Species 0.000 description 10
- 230000000975 bioactive effect Effects 0.000 description 10
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 9
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 206010030113 Oedema Diseases 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 230000005764 inhibitory process Effects 0.000 description 9
- 238000004519 manufacturing process Methods 0.000 description 9
- 239000000203 mixture Substances 0.000 description 9
- 239000000047 product Substances 0.000 description 8
- 230000003612 virological effect Effects 0.000 description 8
- 238000002955 isolation Methods 0.000 description 7
- 229930014626 natural product Natural products 0.000 description 7
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 102100034343 Integrase Human genes 0.000 description 6
- 238000005481 NMR spectroscopy Methods 0.000 description 6
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 6
- 201000011510 cancer Diseases 0.000 description 6
- 230000014509 gene expression Effects 0.000 description 6
- 241000894007 species Species 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 241000228143 Penicillium Species 0.000 description 5
- 230000000259 anti-tumor effect Effects 0.000 description 5
- 230000000840 anti-viral effect Effects 0.000 description 5
- 239000000284 extract Substances 0.000 description 5
- 238000011534 incubation Methods 0.000 description 5
- 244000005700 microbiome Species 0.000 description 5
- 238000001228 spectrum Methods 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 101800000504 3C-like protease Proteins 0.000 description 4
- 102100036464 Activated RNA polymerase II transcriptional coactivator p15 Human genes 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 101800000607 p15 Proteins 0.000 description 4
- 210000004881 tumor cell Anatomy 0.000 description 4
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 3
- 229920001817 Agar Polymers 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 239000008272 agar Substances 0.000 description 3
- 230000010261 cell growth Effects 0.000 description 3
- 238000003919 heteronuclear multiple bond coherence Methods 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 230000004968 inflammatory condition Effects 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 210000004698 lymphocyte Anatomy 0.000 description 3
- 239000003592 new natural product Substances 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- 229930000044 secondary metabolite Natural products 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- JSPUCPNQXKTYRO-LWILDLIXSA-N 2-[[(1r,2s,4as,8as)-1,2,4a,5-tetramethyl-2,3,4,7,8,8a-hexahydronaphthalen-1-yl]methyl]benzene-1,4-diol Chemical compound C([C@@]1(C)[C@H]2[C@](C(=CCC2)C)(C)CC[C@@H]1C)C1=CC(O)=CC=C1O JSPUCPNQXKTYRO-LWILDLIXSA-N 0.000 description 2
- VPRHEJGLNUDEEH-LWILDLIXSA-N 2-[[(1r,2s,4as,8as)-1,2,4a,5-tetramethyl-2,3,4,7,8,8a-hexahydronaphthalen-1-yl]methyl]cyclohexa-2,5-diene-1,4-dione Chemical compound C([C@@]1(C)[C@H]2[C@](C(=CCC2)C)(C)CC[C@@H]1C)C1=CC(=O)C=CC1=O VPRHEJGLNUDEEH-LWILDLIXSA-N 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- HFRPPKGMFYMEJZ-UHFFFAOYSA-N Avarone Natural products CC1CCC2(C)C(=CCCC2(C)C1(C)CC3=CC(=O)C=CC3=O)C HFRPPKGMFYMEJZ-UHFFFAOYSA-N 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 241000700670 Bryozoa Species 0.000 description 2
- 0 C*C(*)(*(C(*=C)(C(*)=C(C)C1=*)O2)C1=C(*)*)C2=O Chemical compound C*C(*)(*(C(*=C)(C(*)=C(C)C1=*)O2)C1=C(*)*)C2=O 0.000 description 2
- YXHKONLOYHBTNS-UHFFFAOYSA-N Diazomethane Chemical compound C=[N+]=[N-] YXHKONLOYHBTNS-UHFFFAOYSA-N 0.000 description 2
- 101710177291 Gag polyprotein Proteins 0.000 description 2
- 208000031886 HIV Infections Diseases 0.000 description 2
- 241000711549 Hepacivirus C Species 0.000 description 2
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 2
- 241000243320 Hydrozoa Species 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 206010025323 Lymphomas Diseases 0.000 description 2
- 102100037611 Lysophospholipase Human genes 0.000 description 2
- 101710125418 Major capsid protein Proteins 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- 238000011785 NMRI mouse Methods 0.000 description 2
- 108010058864 Phospholipases A2 Proteins 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- TXJPJZWNYUQWCP-UHFFFAOYSA-N avarol Natural products CC1CCC2(C)C(=CCCC2(C)C1(C)Cc3cc(O)ccc3O)C TXJPJZWNYUQWCP-UHFFFAOYSA-N 0.000 description 2
- 239000003659 bee venom Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000001142 circular dichroism spectrum Methods 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 238000012364 cultivation method Methods 0.000 description 2
- 239000000824 cytostatic agent Substances 0.000 description 2
- 229940127089 cytotoxic agent Drugs 0.000 description 2
- 230000008260 defense mechanism Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- WGLUMOCWFMKWIL-UHFFFAOYSA-N dichloromethane;methanol Chemical compound OC.ClCCl WGLUMOCWFMKWIL-UHFFFAOYSA-N 0.000 description 2
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 2
- 239000003480 eluent Substances 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 238000004992 fast atom bombardment mass spectroscopy Methods 0.000 description 2
- 239000012894 fetal calf serum Substances 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 238000004362 fungal culture Methods 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 239000002054 inoculum Substances 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 2
- 239000003208 petroleum Substances 0.000 description 2
- 230000036515 potency Effects 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 238000002953 preparative HPLC Methods 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 150000003217 pyrazoles Chemical class 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 238000001896 rotating frame Overhauser effect spectroscopy Methods 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000004611 spectroscopical analysis Methods 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 231100000456 subacute toxicity Toxicity 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- PAWQVTBBRAZDMG-UHFFFAOYSA-N 2-(3-bromo-2-fluorophenyl)acetic acid Chemical compound OC(=O)CC1=CC=CC(Br)=C1F PAWQVTBBRAZDMG-UHFFFAOYSA-N 0.000 description 1
- WHNQTHDJEZTVHS-UHFFFAOYSA-N 3-(1,3-benzothiazol-2-yl)propanoic acid Chemical compound C1=CC=C2SC(CCC(=O)O)=NC2=C1 WHNQTHDJEZTVHS-UHFFFAOYSA-N 0.000 description 1
- CWNPOQFCIIFQDM-UHFFFAOYSA-N 3-nitrobenzyl alcohol Chemical compound OCC1=CC=CC([N+]([O-])=O)=C1 CWNPOQFCIIFQDM-UHFFFAOYSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 108020000948 Antisense Oligonucleotides Proteins 0.000 description 1
- WVVJWXDENDJFEC-CVHNVBPNSA-N C[C@]([C@H]([C@@](C)(C(O)=C(C)C1=O)O2)/C1=C(\C=C\C=C\C)/O)(C2=O)NC(/C=C/C(O)=O)=O Chemical compound C[C@]([C@H]([C@@](C)(C(O)=C(C)C1=O)O2)/C1=C(\C=C\C=C\C)/O)(C2=O)NC(/C=C/C(O)=O)=O WVVJWXDENDJFEC-CVHNVBPNSA-N 0.000 description 1
- SGZIOMUXWRNCLQ-AKNRIYFNSA-N C[C@]([C@H]([C@]1(C)O2)c3c(/C=C/C=C/C)[nH]nc3C(C)=C1O)(C2=O)NC(/C=C/C(O)=O)=O Chemical compound C[C@]([C@H]([C@]1(C)O2)c3c(/C=C/C=C/C)[nH]nc3C(C)=C1O)(C2=O)NC(/C=C/C(O)=O)=O SGZIOMUXWRNCLQ-AKNRIYFNSA-N 0.000 description 1
- 101100283604 Caenorhabditis elegans pigk-1 gene Proteins 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 108010062580 Concanavalin A Proteins 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 206010017533 Fungal infection Diseases 0.000 description 1
- 230000005526 G1 to G0 transition Effects 0.000 description 1
- 241000725303 Human immunodeficiency virus Species 0.000 description 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- 208000008771 Lymphadenopathy Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 208000031888 Mycoses Diseases 0.000 description 1
- 240000001307 Myosotis scorpioides Species 0.000 description 1
- 208000001388 Opportunistic Infections Diseases 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- 239000012979 RPMI medium Substances 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 208000006268 Sarcoma 180 Diseases 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- OIRDTQYFTABQOQ-UHTZMRCNSA-N Vidarabine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O OIRDTQYFTABQOQ-UHTZMRCNSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000001919 adrenal effect Effects 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- 150000001408 amides Chemical group 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000719 anti-leukaemic effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000000074 antisense oligonucleotide Substances 0.000 description 1
- 238000012230 antisense oligonucleotides Methods 0.000 description 1
- OIRDTQYFTABQOQ-UHFFFAOYSA-N ara-adenosine Natural products Nc1ncnc2n(cnc12)C1OC(CO)C(O)C1O OIRDTQYFTABQOQ-UHFFFAOYSA-N 0.000 description 1
- 101150035354 araA gene Proteins 0.000 description 1
- 230000003816 axenic effect Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 210000003679 cervix uteri Anatomy 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 230000000973 chemotherapeutic effect Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 238000011281 clinical therapy Methods 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 239000007799 cork Substances 0.000 description 1
- 238000006352 cycloaddition reaction Methods 0.000 description 1
- 230000001085 cytostatic effect Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 230000002900 effect on cell Effects 0.000 description 1
- 125000002587 enol group Chemical group 0.000 description 1
- WKZOALAUKQNFNG-UHFFFAOYSA-N epoxysorbicillinol Natural products CC=CC=CC(=O)C12OC1C(C)(O)C(=O)C(=C2O)C WKZOALAUKQNFNG-UHFFFAOYSA-N 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 210000003953 foreskin Anatomy 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 238000001511 high performance liquid chromatography nuclear magnetic resonance spectroscopy Methods 0.000 description 1
- 238000010262 high-speed countercurrent chromatography Methods 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 150000002596 lactones Chemical group 0.000 description 1
- 238000004460 liquid liquid chromatography Methods 0.000 description 1
- 238000000622 liquid--liquid extraction Methods 0.000 description 1
- 208000018555 lymphatic system disease Diseases 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- JTJJJLSLKZFEPJ-ZAYCRUKZSA-N meleagrin Chemical compound C([C@]1(C2=CC=CC=C2N([C@@]21NC1=O)OC)C(C)(C)C=C)=C(O)C(=O)N2\C1=C\C1=CNC=N1 JTJJJLSLKZFEPJ-ZAYCRUKZSA-N 0.000 description 1
- JTJJJLSLKZFEPJ-GOTSBHOMSA-N meleagrin Natural products CON1c2ccccc2[C@@]3(C=C(O)C(=O)N4C(=Cc5c[nH]cn5)C(=O)N[C@@]134)C(C)(C)C=C JTJJJLSLKZFEPJ-GOTSBHOMSA-N 0.000 description 1
- 108010064507 meleagrin Proteins 0.000 description 1
- JTJJJLSLKZFEPJ-DHIUTWEWSA-N meleagrine Natural products CON1c2ccccc2[C@]3(C=C(O)C(=O)N4C(=Cc5c[nH]cn5)C(=O)N[C@]134)C(C)(C)C=C JTJJJLSLKZFEPJ-DHIUTWEWSA-N 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- GBMDVOWEEQVZKZ-UHFFFAOYSA-N methanol;hydrate Chemical compound O.OC GBMDVOWEEQVZKZ-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 1
- 239000005445 natural material Substances 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- SPWSUFUPTSJWNG-UHFFFAOYSA-N roquefortine C Natural products C=1C=CC=C2C=1NC1C2(C(C)(C=C)C)CC(C(N2)=O)N1C(=O)C2=CC1=CN=CN1 SPWSUFUPTSJWNG-UHFFFAOYSA-N 0.000 description 1
- 239000007289 sea water agar Substances 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 229930192193 sorbicillactone Natural products 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000004114 suspension culture Methods 0.000 description 1
- 230000031068 symbiosis, encompassing mutualism through parasitism Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- 229910021654 trace metal Inorganic materials 0.000 description 1
- 230000001173 tumoral effect Effects 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/86—Benzo [b] furans; Hydrogenated benzo [b] furans with an oxygen atom directly attached in position 7
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Virology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- AIDS & HIV (AREA)
- Hematology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Furan Compounds (AREA)
Priority Applications (10)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10238257A DE10238257B4 (de) | 2002-08-21 | 2002-08-21 | Sorbicillacton A und Sorbicillacton-A-Derivate, Verfahren zu ihrer Herstellung und sie enthaltende Arzneimittel |
| PCT/EP2003/007805 WO2004026854A1 (de) | 2002-08-21 | 2003-07-17 | Sorbicillacton-a-derivate zur behandlung von tumor- und viruserkrankungen |
| US10/525,685 US20060111420A1 (en) | 2002-08-21 | 2003-07-17 | Sorbicillactone-a derivatives for the treatment of tumour and viral diseases |
| CA002496386A CA2496386A1 (en) | 2002-08-21 | 2003-07-17 | Sorbicillactone-a derivatives for the treatment of tumour and viral diseases |
| AU2003250985A AU2003250985A1 (en) | 2002-08-21 | 2003-07-17 | Sorbicillactone-a derivatives for the treatment of tumour and viral diseases |
| DE50305776T DE50305776D1 (de) | 2002-08-21 | 2003-07-17 | Sorbicillacton-a-derivate zur behandlung von tumor- und viruserkrankungen |
| EP03797201A EP1532129B1 (de) | 2002-08-21 | 2003-07-17 | Sorbicillacton-a-derivate zur behandlung von tumor- und viruserkrankungen |
| AT03797201T ATE346057T1 (de) | 2002-08-21 | 2003-07-17 | Sorbicillacton-a-derivate zur behandlung von tumor- und viruserkrankungen |
| JP2004536901A JP2006503049A (ja) | 2002-08-21 | 2003-07-17 | ソルビシルラクトンａおよびソルビシルラクトンａ誘導体、これらの製造方法、これらを含有する薬剤、およびこれらの使用 |
| ZA200502226A ZA200502226B (en) | 2002-08-21 | 2005-03-16 | Sorbicillactone-A derivatives for the treatment oftumour and viral diseases. |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10238257A DE10238257B4 (de) | 2002-08-21 | 2002-08-21 | Sorbicillacton A und Sorbicillacton-A-Derivate, Verfahren zu ihrer Herstellung und sie enthaltende Arzneimittel |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE10238257A1 DE10238257A1 (de) | 2004-03-11 |
| DE10238257B4 true DE10238257B4 (de) | 2007-04-19 |
Family
ID=31501834
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE10238257A Expired - Fee Related DE10238257B4 (de) | 2002-08-21 | 2002-08-21 | Sorbicillacton A und Sorbicillacton-A-Derivate, Verfahren zu ihrer Herstellung und sie enthaltende Arzneimittel |
| DE50305776T Expired - Fee Related DE50305776D1 (de) | 2002-08-21 | 2003-07-17 | Sorbicillacton-a-derivate zur behandlung von tumor- und viruserkrankungen |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE50305776T Expired - Fee Related DE50305776D1 (de) | 2002-08-21 | 2003-07-17 | Sorbicillacton-a-derivate zur behandlung von tumor- und viruserkrankungen |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20060111420A1 (enExample) |
| EP (1) | EP1532129B1 (enExample) |
| JP (1) | JP2006503049A (enExample) |
| AT (1) | ATE346057T1 (enExample) |
| AU (1) | AU2003250985A1 (enExample) |
| CA (1) | CA2496386A1 (enExample) |
| DE (2) | DE10238257B4 (enExample) |
| WO (1) | WO2004026854A1 (enExample) |
| ZA (1) | ZA200502226B (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102004004901B4 (de) * | 2004-01-30 | 2006-01-05 | Johannes-Gutenberg-Universität Mainz | Verfahren zur Herstellung von Sorbicillacton A |
| DE102004005106A1 (de) * | 2004-02-02 | 2005-08-18 | Johannes-Gutenberg-Universität Mainz | Sorbifuranone, Sorbivineton, Sorbivinetol und Derivate dieser Verbindungen, Verfahren zu ihrer Herstellung, sie enthaltende Arzneimittel und deren Verwendung |
| KR102438137B1 (ko) | 2015-12-02 | 2022-08-30 | 에스케이이노베이션 주식회사 | 내열성 및 셧다운 특성이 우수한 이차전지용 분리막 |
| CN110037054B (zh) * | 2019-04-16 | 2021-04-20 | 云南大学 | 一种提高烟草抗病性的水溶性多肽诱导剂及其应用 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ332340A (en) * | 1996-05-20 | 2000-04-28 | Darwin Discovery Ltd | 4-(aryl or heteroaryl) substituted benzofurancarboxamide derivatives and medicaments |
| AU2001293048A1 (en) * | 2000-09-26 | 2002-04-08 | The Johns Hopkins University | Antiviral compositions and methods of use |
-
2002
- 2002-08-21 DE DE10238257A patent/DE10238257B4/de not_active Expired - Fee Related
-
2003
- 2003-07-17 DE DE50305776T patent/DE50305776D1/de not_active Expired - Fee Related
- 2003-07-17 CA CA002496386A patent/CA2496386A1/en not_active Abandoned
- 2003-07-17 AT AT03797201T patent/ATE346057T1/de not_active IP Right Cessation
- 2003-07-17 AU AU2003250985A patent/AU2003250985A1/en not_active Abandoned
- 2003-07-17 US US10/525,685 patent/US20060111420A1/en not_active Abandoned
- 2003-07-17 EP EP03797201A patent/EP1532129B1/de not_active Expired - Lifetime
- 2003-07-17 JP JP2004536901A patent/JP2006503049A/ja not_active Withdrawn
- 2003-07-17 WO PCT/EP2003/007805 patent/WO2004026854A1/de not_active Ceased
-
2005
- 2005-03-16 ZA ZA200502226A patent/ZA200502226B/en unknown
Non-Patent Citations (1)
| Title |
|---|
| Chem. Abstr. 134(2001), 311008 * |
Also Published As
| Publication number | Publication date |
|---|---|
| EP1532129A1 (de) | 2005-05-25 |
| EP1532129B1 (de) | 2006-11-22 |
| JP2006503049A (ja) | 2006-01-26 |
| ZA200502226B (en) | 2006-02-22 |
| AU2003250985A1 (en) | 2004-04-08 |
| US20060111420A1 (en) | 2006-05-25 |
| DE10238257A1 (de) | 2004-03-11 |
| ATE346057T1 (de) | 2006-12-15 |
| WO2004026854A1 (de) | 2004-04-01 |
| DE50305776D1 (de) | 2007-01-04 |
| CA2496386A1 (en) | 2004-04-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69331922T2 (de) | Zyklische Peptide mit antifungischer Wirkung und Verfahren zu ihrer Herstellung | |
| DE69532475T2 (de) | Krebs hemmende peptide | |
| DE69321087T2 (de) | Alpha-aminoketon Derivate | |
| DE69712101T2 (de) | Gegen das hepatitis b-virus aktive genipinin-derivate | |
| DE60130769T2 (de) | Förderer der nervenregeneration die als aktiven bestandteil einen semaphorinhemmer enthalten | |
| DE2858802C2 (de) | Arzneimittel zur unterdrueckung von tumorzellwachstum | |
| DE2640275A1 (de) | Pharmakologisch wirksame substanz aus labiaten | |
| DE3109335C2 (de) | Ebelacton A und B, Verfahren zu deren Herstellung und diese Verbindungen enthaltende pharmazeutische Mittel | |
| EP0432595A1 (de) | Neue Peptide, ihre Herstellung und ihre Verwendung in Arzneimitteln | |
| DE10238257B4 (de) | Sorbicillacton A und Sorbicillacton-A-Derivate, Verfahren zu ihrer Herstellung und sie enthaltende Arzneimittel | |
| DE3853804T2 (de) | Zearalanol-Derivate mit anabolytischer Wirkung. | |
| EP0349609B1 (de) | Aminosäureester, verfahren zu ihrer herstellung und ihre verwendung | |
| DE69320367T2 (de) | Therapeutische verbindungen für die behandlung von krankheiten, die mit einem glutathion-defizit assoziiert sind, herstellungsprozess und diese enthaltene pharmazeutische zusammensetzungen | |
| DE60108359T2 (de) | Biologisch wirksame, analoge verbindungen von discodermoliden | |
| DE60029982T2 (de) | Antimykotische enediyne | |
| CH637123A5 (en) | Monocyclic peptide, its preparation and use | |
| JP2011046734A (ja) | セマフォリン阻害剤としての新規化合物 | |
| DE102004004901B4 (de) | Verfahren zur Herstellung von Sorbicillacton A | |
| DE102004002884B4 (de) | Aspernigrin B und Aspernigrin-B-Derivate, sie enthaltende pharmazeutische Zusammensetzungen und deren Verwendung | |
| DE3875835T2 (de) | Antivirale, antitumoraktive und fungizide zusammensetzungen. | |
| DE102004005106A1 (de) | Sorbifuranone, Sorbivineton, Sorbivinetol und Derivate dieser Verbindungen, Verfahren zu ihrer Herstellung, sie enthaltende Arzneimittel und deren Verwendung | |
| JP2988937B2 (ja) | 海洋源由来の新規の抗腫瘍性及び抗ウイルス性組成物 | |
| DE3427383A1 (de) | Avaron und avaron-derivate, verfahren zu ihrer herstellung, sie enthaltende arzneimittel und deren verwendung | |
| DE69214737T2 (de) | Antibiotika NK374186A, NK374186B, NK374186B3 und NK374186C3, Verfahren zu ihrer Herstellung und ihre Verwendung | |
| DE68906248T2 (de) | Antagonisten fuer den platelet-aktivierungsfaktor, phomactine genannt, ihre herstellung und verwendung. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| OP8 | Request for examination as to paragraph 44 patent law | ||
| 8181 | Inventor (new situation) |
Inventor name: MUELLER, WERNER E.G., PROF. DR., 65203 WIESBADEN, D Inventor name: MUEHLBACHER, JOERG, 79106 FREIBURG, DE Inventor name: LANG, GERHARD, 97072 WUERZBURG, DE Inventor name: BRINGMANN, GERHARD, PROF. DR., 97074 WUERZBURG, DE Inventor name: STEFFENS, STEFAN, 52072 AACHEN, DE Inventor name: SCHAUMANN, KARSTEN, DR., 27578 BREMERHAVEN, DE |
|
| 8364 | No opposition during term of opposition | ||
| 8339 | Ceased/non-payment of the annual fee |